438
Participants
Start Date
April 30, 2004
Primary Completion Date
September 30, 2006
Study Completion Date
September 30, 2006
larotaxel (RPR109881, XRP9881)
capecitabine
Nyack
Utica
Pittsburgh
Kttaning
Hershey
Dunmore
Kingston
Philadelphia
Philadelphia
Philadelphia
Newark
Baltimore
Annapolis
Arlington
Abingdon
Huntington
Winston-Salem
Chapel Hill
Raleigh
Greenville
Charlotte
Charlotte
Wilmington
Charleston
Charleston
Greenville
Lawrenceville
Marietta
Roswell
Macon
Jacksonville
Gainsville
Orlando
Fort Lauderdale
Fort Lauderdale
West Palm Beach
Lake Worth
Birmingham
Nashville
Danville
Lexington
Hazard
Worthington
Cleveland
Cleveland
Cincinnati
Fort Wayne
New Albany
Southfield
Saint Joseph
Bismarck
Billings
Chicago
Peoria
Centralia
St Louis
St Louis
Skokie
Lafayette
Shreveport
Little Rock
Richardson
Dallas
Fort Worth
Tucson
Los Angeles
Redondo Beach
Long Beach
Northridge
Burbank
Monterey Park
Pomona
Vista
San Diego
Fountain Valley
Fullerton
Oxnard
Santa Barbara
Porterville
Bakersfield
Fresno
San Francisco
Concord
Gilroy
Soquel
Kirkland
Spokane
New London
Hackensack
Buenos Aires
Capital Federal
Santa Fe
Melbourne
Perth
St Leonards
Sydney
Bludesch
Vienna
Sorocaba
São Paulo
St. John's
Lévis
Québec
Montreal
Ontario
Ottawa
Québec
Las Condes, Santiago
Santiago
Bogotá
Cali Valle
Medellín
Hradec Králové
Nora Ves Pod Plesi
Ostrava
Kemi
Oulu
Besançon
Lyon
Marseille
Montpellier
Nice
Paris
Saint-Cloud
Saint-Herblain
Aschaffenburg
Berlin
Frankfurt
Halle
Heidelberg
Kiel
Munchen Bayern
Munich
Oldenberg
Budapest
Szeged
Ashkelon
Beersheba
Haifa
Tel Aviv
Tel Litwinsky
Bologna
Cuneo
Largo Agostino Gemelli
Livorno
Modena
Napoli
Novara
Palermo
Pavia
Sassari
Mexico DF Distrio Federal
Tuluea Estand de Mexico
Auckland
Christchurch
Kracow
Warsaw
Porto
Beja
Coimbra
Lisbon
Bucharest
Cluj-Napoca
Craiova
Maribor
Capetown
Durban
Johannesburg
Parktown
Pretoria
Gyeonggi-do
Seoul
Alicante
Jaén
Madrid
Navarra
Valencia
Taipai
Taoyuang
Birmingham
Cardiff
Bristol
Ipswich
London
Manchester
Nottingham
Surrey
Lead Sponsor
Sanofi
INDUSTRY